Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors

Core Insights - Century Therapeutics has appointed Dr. Han Lee and Dr. Martin Murphy to its Board of Directors, enhancing its leadership team at a critical time for the company [1][2] Company Overview - Century Therapeutics is a biotechnology company focused on developing induced pluripotent stem cell (iPSC)-derived cell therapies aimed at treating autoimmune diseases and cancer [4] - The company utilizes its iPSC cell foundry and a novel immune evasion engineering technology called Allo-Evasion™ to create off-the-shelf cell therapies, which are expected to improve patient access and offer advantages over existing therapies [4] Leadership Appointments - Dr. Han Lee will serve on the Audit and Compensation Committees, bringing extensive experience in capital formation and corporate development from his previous roles at ImmPACT Bio, Neogene Therapeutics, and AstraZeneca [1][2] - Dr. Martin Murphy will be part of the Compensation and Nominating and Corporate Governance Committees, with a strong background in life science investment and company creation from his roles at Syncona and MVM Life Science Partners [1][3] Strategic Focus - The company is prioritizing the advancement of its iPSC-derived cell therapy programs, particularly CNTY-813, which is being developed as a potentially curative treatment for type 1 diabetes [2]